Cat. No.: HY-N0695

Schisantherin B

(Synonyms: Gomisin-B; Wuweizi ester-B; Schisantherin-B)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Schisantherin B (Gomisin-B) is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of tau protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression.

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 58546-55-7
Formula: C₂₈H₃₄O₉
Molecular Weight:514.56

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Schisantherin B Chemical Structure

CAS No.: 58546-55-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All PI3K Isoforms :

All Akt Isoforms :

All mTOR Isoforms :

All GSK-3 Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
H9	EC₅₀	40 μM Compound: schisantherin B	Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA	[PMID: 17190445]
H9	IC₅₀	>49 μM Compound: schisantherin B	Cytotoxicity against human H9 cells after 4 days Cytotoxicity against human H9 cells after 4 days	[PMID: 17190445]

In Vitro

Schisantherin B (25 μM; 4 h) increases viability, inhibits apoptosis, and activates the PI3K/AKT pathway in H₂O₂-treated PC12 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

PC12 cells
Concentration:

25 μM (co-incubated with 90 μM H₂O₂)
Incubation Time:

4 hours
Result:

Increased PC12 cell viability to 66.15% (compared to 40.86% in the H₂O₂-only group).
Reduced the apoptotic cell percentage to 5.84% (compared to 10.81% in the H₂O₂-only group).
Significantly decreased mean fluorescence intensity (MFI) of cleaved caspase-3.
Significantly upregulated MFI of phosphorylated PI3K (p-PI3K) and phosphorylated AKT (p-AKT) compared to the H₂O₂-only group.

In Vivo

Schisantherin B (15 mg/kg; i.p.; once daily for 10 consecutive days) exerts antidepressant-like effects in mice with depression induced by the forced swim test (FST), ameliorates FST-induced short-term memory impairment, and restores the activities of hippocampal GLT-1 and the PI3K/AKT/mTOR pathway^[1].
Schisantherin B (15 mg/kg; intravenous injection; three times daily) improves motor function, alleviates tissue damage, inhibits apoptosis and inflammatory responses, and activates the PI3K/AKT pathway to mitigate secondary injury, thereby promoting recovery in a mouse model of spinal cord injury^[2].
Schisantherin B (0.015-0.15 mg/kg; intracerebroventricular injection; once daily for 5 consecutive days) dose-dependently ameliorates Aβ_1-42-induced cognitive decline and neuronal damage in mice by restoring the functions of GLT-1 and GSK3β and reducing excessive tau phosphorylation^[3].
Schisantherin B (0.15 mg/kg; intracerebroventricular injection, once daily for 5 consecutive days) enhances spatial learning ability in healthy mice without altering their basal motor activity or inducing neuronal or biochemical abnormalities^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KM mice (male, 10-week old, 20-25 g, forced swimming test-induced depression)^[1]
Dosage:

15 mg/kg
Administration:

i.p.; daily; 10 days
Result:

Significantly reduced immobility time and climbing time, and significantly increased swimming time relative to the control group.
Significantly increased spontaneous alternation behavior relative to the control group on day 19; by day 20, spontaneous alternation behavior was comparable to the normal (non-FST) group; by day 27, no differences in alternation behavior were observed between groups.
Significantly increased total distance traveled relative to the control group on day 20.
Significantly restored hippocampal levels of GLT-1, P-PI3K/PI3K, P-AKT/AKT, and P-mTOR/mTOR relative to the control group on day 19.

Animal Model:

C57BL/6J Nifdc (8-10-week-old; spinal cord injury model via 12.5 g weight-drop procedure under ketamine/xylazine anesthesia)^[2]
Dosage:

15 mg/kg
Administration:

i.v.; three times daily
Result:

Increased Basso Mouse Scale scores significantly at 21 and 28 days post-injury compared to untreated mice.
Increased hindlimb stride length to ~36 mm and reduced stride width to ~21 mm compared to untreated mice.
Reduced spinal cord cavity size, preserved spinal cord tissue integrity, and increased the number of surviving ventral horn motor neurons.
Reduced the percentage of apoptotic cells and suppressed microglial activation.
Decreased concentrations of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α, and increased concentrations of anti-inflammatory cytokine IL-10.
Increased the proportion of p-PI3K-positive neurons to ~0.5, p-AKT-positive neurons to ~0.45, and upregulated p-PI3K/PI3K and p-AKT/AKT protein expression ratios compared to untreated mice.

Animal Model:

KM mice (male, 10-week-old, 25-30 g, intracerebroventricular injection of aggregated Aβ_1-42 peptide)^[3]
Dosage:

0.015 mg/kg; 0.15 mg/kg
Administration:

i.c.v.; daily; 5 days
Result:

Showed no significant effect on locomotor activity.
Significantly relieved Aβ_1-42-induced reduction in spontaneous alternation behavior in the Y-maze test, with 0.15 mg/kg showing greater efficacy than 0.015 mg/kg.
Significantly ameliorated Aβ_1-42-induced increases in escape latency and escape distance in the Morris water maze place navigation test on days 4 and 5 at 0.15 mg/kg.
Restored hippocampal GLT-1 levels to 58.18 pg/mL, cerebral cortex GLT-1 levels to 98.05 pg/mL, reduced hippocampal GSK3β levels to 80.56 pmol/l, cerebral cortex GSK3β levels to 181.22 pmol/l, and restored hippocampal p-GSK3β levels to 217.24 ng/l, cerebral cortex p-GSK3β levels to 215.83 ng/l at 0.15 mg/kg.
Reduced hippocampal p-tau levels to 192.32 ng/l and cerebral cortex p-tau levels to 179.43 ng/l at 0.15 mg/kg.
Normalized hippocampal and cerebral cortex Aβ_1-42 levels at 0.15 mg/kg.
Restored hippocampal GLT-1/β-actin, GSK3β/β-actin, p-GSK3β/β-actin, and p-tau/β-actin ratios to near-normal levels at 0.15 mg/kg.
Inhibited Aβ_1-42-induced hippocampal neuronal damage (shrunken nuclei, swollen neuronal bodies) as observed via H.E.
and Nissl staining at 0.15 mg/kg.
Reduced escape latency in the Morris water maze place navigation test in healthy mice treated with 0.15 mg/kg compared to normal untreated mice.
Maintained near-normal hippocampal and cerebral cortex GLT-1, GSK3β, p-GSK3β, Aβ_1-42, and p-tau levels in healthy mice treated with 0.15 mg/kg.
Showed intact, ordered hippocampal neurons in healthy mice treated with 0.15 mg/kg.

Animal Model:

KM mice (male, 10-week-old, 25-30 g)^[3]
Dosage:

0.15 mg/kg
Administration:

i.c.v.; daily; 5 days
Result:

Showed no significant effect on locomotor activity or Y-maze spontaneous alternation behavior.
Reduced escape latency in the Morris water maze place navigation test compared to normal untreated mice.
Spent more time in the target quadrant during the Morris water maze spatial probe test.
Maintained near-normal hippocampal and cerebral cortex GLT-1, GSK3β, p-GSK3β, Aβ_1-42, and p-tau levels.
Showed intact, ordered hippocampal neurons.

Chemical Information

CAS No. 58546-55-7
Appearance Solid
Molecular Weight 514.56
Formula C₂₈H₃₄O₉
Color White to off-white
SMILES

O=C(OC(C(C)(O)C(C)C1)C2=CC(OC)=C(OC)C(OC)=C2C3=C1C=C4OCOC4=C3OC)/C(C)=C/C
Synonyms

Gomisin-B; Wuweizi ester-B; Schisantherin-B
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (97.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9434 mL

9.7170 mL

19.4341 mL

5 mM

0.3887 mL

1.9434 mL

3.8868 mL

10 mM

0.1943 mL

0.9717 mL

1.9434 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Xu M, et al. Schisantherin B Improves the Pathological Manifestations of Mice Caused by Behavior Desperation in Different Ages-Depression with Cognitive Impairment. Biomol Ther (Seoul). 2019;27(2):160-167. [Content Brief]

[2]. Wang W, et al. Schisantherin B exerts therapeutic effects on spinal cord injury via the PI3K/AKT signaling pathway. Pak J Pharm Sci. 2026;39(1):232-241. [Content Brief]

[3]. Xu M, et al. Schisantherin B ameliorates Aβ_1-42-induced cognitive decline via restoration of GLT-1 in a mouse model of Alzheimer's disease. Physiol Behav. 2016;167:265-273. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9434 mL	9.7170 mL	19.4341 mL	48.5852 mL
	5 mM	0.3887 mL	1.9434 mL	3.8868 mL	9.7170 mL
	10 mM	0.1943 mL	0.9717 mL	1.9434 mL	4.8585 mL
	15 mM	0.1296 mL	0.6478 mL	1.2956 mL	3.2390 mL
	20 mM	0.0972 mL	0.4859 mL	0.9717 mL	2.4293 mL
	25 mM	0.0777 mL	0.3887 mL	0.7774 mL	1.9434 mL
	30 mM	0.0648 mL	0.3239 mL	0.6478 mL	1.6195 mL
	40 mM	0.0486 mL	0.2429 mL	0.4859 mL	1.2146 mL
	50 mM	0.0389 mL	0.1943 mL	0.3887 mL	0.9717 mL
	60 mM	0.0324 mL	0.1620 mL	0.3239 mL	0.8098 mL
	80 mM	0.0243 mL	0.1215 mL	0.2429 mL	0.6073 mL

Schisantherin B

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Schisantherin B

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Schisantherin B

All PI3K Isoforms